Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Challenges of antiretroviral treatment in transient and drug-using populations: The SUN study
Autore:
Sension, MG; Farthing, C; Shaffer, AG; Graham, E; Siemon-Hryczyk, P; Pilson, RS;
Indirizzi:
N Broward Hosp Dist, Ft Lauderdale, FL USA N Broward Hosp Dist Ft Lauderdale FL USA osp Dist, Ft Lauderdale, FL USA AIDS Healthcare Fdn, Res Ctr, Los Angeles, CA USA AIDS Healthcare Fdn LosAngeles CA USA Fdn, Res Ctr, Los Angeles, CA USA Roche Labs Inc, Nutley, NJ USA Roche Labs Inc Nutley NJ USARoche Labs Inc, Nutley, NJ USA
Titolo Testata:
AIDS PATIENT CARE AND STDS
fascicolo: 3, volume: 15, anno: 2001,
pagine: 129 - 136
SICI:
1087-2914(200103)15:3<129:COATIT>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; SOFT GELATIN FORMULATION; PROTEASE INHIBITORS; THERAPY; USERS; COMBINATION; SAQUINAVIR; ADHERENCE; INFECTION; BARRIERS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Sension, MG HIV Clin Res, 1101 NW 1st St, Ft Lauderdale, FL 33316 USA HIV Clin Res 1101 NW 1st St Ft Lauderdale FL USA 33316 316 USA
Citazione:
M.G. Sension et al., "Challenges of antiretroviral treatment in transient and drug-using populations: The SUN study", AIDS PAT CA, 15(3), 2001, pp. 129-136

Abstract

This is an open-label, single-arm, phase 3b study (part of phase 3 development) to evaluate the efficacy and safety of Fortovase-soft gelatin formulation (saquinavir-SGC), combined with zidovudine (ZDV) and lamivudine (3TC),human immune deficiency virus type 1 in (HIV-1)-positive, antiretroviral-naive individuals. Forty-two HIV-1-positive adults with plasma HIV RNA >10,000 copies per milliliter (Roche Amplicor HIV Monitor assay) and CD4 cell count >100 cells/mm(3) were treated with SQV-SGC, 1200 mg three times per day; ZDV, 300 mg; and 3TC, 150 mg each twice per day for 48 weeks. High proportions were drug users (26%), demonstrated psychiatric disorders (alcohol abuse [14%]/depression [14%]), or were inadequately housed (5%). At 48 weeks,50% of patients achieved viral suppression <400 copies per milliliter with43% <20 copies per milliliter using an intent-to-treat analysis (missing values counted as virological failures). Corresponding proportions for patients remaining on therapy at 48 weeks were 91% <400 copies per milliliter and 78% <20 copies per milliliter. Most adverse events were mild. Saquinavir-SGC combined with ZDV and 3TC, achieved potent and durable HIV RNA suppression and was well tolerated over 48 weeks in an antiretroviral-naive population including high proportions of individuals considered difficult to treat, such as drug users, people with psychiatric problems and homeless individuals.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 02:57:34